文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

医院私募股权收购与医保受益人急性内科疾病结局的关联

Association Between Hospital Private Equity Acquisition and Outcomes of Acute Medical Conditions Among Medicare Beneficiaries.
PubMed 文献 · JAMA Netw Open · 2022-04-01
一句话结论2001-2018年医保数据显示,私募股权收购医院与急性内科疾病患者结局无实质关联,但急性心梗患者住院及30天死亡率有中等程度改善。

该横断面研究采用广义双重差分法,比较2001年1月1日至2018年12月31日期间私募股权收购与非收购短期急性病医院收治的2109万1222例66岁及以上医保受益人,涵盖急性心梗、急性卒中、慢阻肺急性加重、充血性心衰急性加重和肺炎5种急性内科疾病。结果显示,私募股权收购医院与患者合并症负担、住院时间、30天再入院和30天费用无实质关联;急性卒中患者合并症负担轻度下降(差值-0.04个标准差,95%CI -0.004至-0.07),急性心梗患者住院死亡率(差值-1.14个百分点,95%CI -1.86至-0.42)和30天死亡率(差值-1.41个百分点,95%CI -2.26至-0.56)降幅更大。结论认为私募股权收购与所考察的患者层面结局无实质关联,但与急性心梗患者死亡率的中等程度改善相关。

要点

  • 急性心梗患者中,私募股权收购医院较非收购医院住院死亡率降幅更大(差值-1.14个百分点,95%CI -1.86至-0.42)。
  • 急性心梗患者30天死亡率在收购医院较非收购医院降幅更大(差值-1.41个百分点,95%CI -2.26至-0.56)。
  • 全部5种急性内科疾病的30天费用和再入院率在收购与非收购医院间保持不变。
  • 急性卒中患者合并症负担在收购医院轻度下降(差值-0.04个标准差,95%CI -0.004至-0.07),其余4种疾病无变化。
  • 上述估计在所有稳健性评估和亚组分析中方向和程度保持一致。

适用人群与场景

  • 66岁及以上医保受益人,因急性心梗、急性卒中、慢阻肺急性加重、充血性心衰急性加重或肺炎5种急性内科疾病之一住院。
  • 2001年1月1日至2018年12月31日期间入住短期急性病医院,数据覆盖收购前至少3年至收购后3年。

研究设计与关键结果

  • 研究类型:横断面研究,采用广义双重差分法,比较私募股权收购与非收购短期急性病医院。
  • 样本量:共21 091 222例医保受益人,其中非收购医院20 431 486例,收购医院659 736例;平均(标准差)年龄79.45(7.95)岁,男性11 727 439例(55.6%),双重保险4 550 012例(21.6%),少数种族或族裔2 996 560例(14.2%),包括黑人2 085 128例(9.9%)和西班牙裔371 648例(1.8%),白人18 094 662例(85.8%)。
  • 疾病构成:急性心梗3 083 760例(14.6%),急性卒中2 835 777例(13.4%),慢阻肺急性加重3 674 477例(17.4%),充血性心衰急性加重5 868 034例(27.8%),肺炎5 629 174例(26.7%)。
  • 合并症负担:急性卒中患者在收购医院较非收购医院轻度下降(差值-0.04个标准差,95%CI -0.004至-0.07个标准差),其余4种疾病无变化。
  • 急性心梗患者住院死亡率在收购医院较非收购医院降幅更大(差值-1.14个百分点,95%CI -1.86至-0.42个百分点)。
  • 急性心梗患者30天死亡率在收购医院较非收购医院降幅更大(差值-1.41个百分点,95%CI -2.26至-0.56个百分点)。
  • 全部疾病的30天费用和再入院率在收购与非收购医院间保持不变。
  • 所有稳健性评估和亚组分析中估计的方向和程度保持一致。

证据类型、等级与局限

  • 证据类型:横断面研究,采用广义双重差分法,并纳入机构与医院服务区固定效应;稳健性分析额外纳入患者来源县固定效应,并进行了两项亚组分析(仅纳入至少发生1例私募股权收购的医院转诊区域内的医院;按参与2006年美国医院公司收购进行分层)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,私募股权收购与所考察的患者层面结局无实质关联,但与医保受益人急性心梗住院死亡率的中等程度改善相关。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: As private equity (PE) acquisitions of short-term acute care hospitals (ACHs) continue, their impact on the care of medically vulnerable older adults remains largely unexplored.

OBJECTIVE: To investigate the association between PE acquisition of ACHs and access to care, patient outcomes, and spending among Medicare beneficiaries hospitalized with acute medical conditions.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used a generalized difference-in-differences approach to compare 21 091 222 patients admitted to PE-acquired vs non-PE-acquired short-term ACHs between January 1, 2001, and December 31, 2018, at least 3 years before to 3 years after PE acquisition. The analysis was conducted between December 28, 2020, and February 1, 2022. Differences were estimated using both facility and hospital service area fixed effects. To assess the robustness of findings, regressions were reestimated after including fixed effects of patient county of origin to account for geographic differences in underlying health risks. Two subset analyses were also conducted: (1) an analysis including only hospitals in hospital referral regions with at least 1 PE acquisition and (2) an analysis stratified by participation in the Hospital Corporation of America 2006 acquisition. The study included Medicare beneficiaries 66 years and older who were hospitalized with 1 of 5 acute medical conditions: acute myocardial infarction (AMI), acute stroke, chronic obstructive pulmonary disease exacerbation, congestive heart failure exacerbation, and pneumonia.

EXPOSURES: Acquisition of hospitals by PE firms.

MAIN OUTCOMES AND MEASURES: Comorbidity burden (measured by Elixhauser comorbidity score), hospital length of stay, in-hospital mortality, 30-day mortality, 30-day readmission, and 30-day episode payments.

RESULTS: Among 21 091 222 total Medicare beneficiaries admitted to ACHs between 2001 and 2018, 20 431 486 patients received care at non-PE-acquired hospitals, and 659 736 received care at PE-acquired hospitals. Across all admissions, the mean (SD) age was 79.45 (7.95) years; 11 727 439 patients (55.6%) were male, and 4 550 012 patients (21.6%) had dual insurance; 2 996 560 (14.2%) patients were members of racial or ethnic minority groups, including 2 085 128 [9.9%] Black and 371 648 [1.8%] Hispanic; 18 094 662 patients (85.8%) were White. Overall, 3 083 760 patients (14.6%) were hospitalized with AMI, 2 835 777 (13.4%) with acute stroke, 3 674 477 (17.4%) with chronic obstructive pulmonary disease exacerbation, 5 868 034 (27.8%) with congestive heart failure exacerbation, and 5 629 174 (26.7%) with pneumonia. Comorbidity burden decreased slightly among patients admitted with acute stroke (difference, -0.04 SDs; 95% CI, -0.004 to -0.07 SDs) at acquired hospitals compared with nonacquired hospitals but was unchanged across the other 4 conditions. Among patients with AMI, a greater decrease in in-hospital mortality was observed in PE-acquired hospitals compared with non-PE-acquired hospitals (difference, -1.14 percentage points, 95% CI, -1.86 to -0.42 percentage points). In addition, a greater decrease in 30-day mortality (difference, -1.41 percentage points; 95% CI, -2.26 to -0.56 percentage points) was found at acquired vs nonacquired hospitals. However, 30-day spending and readmission rates remained unchanged across all conditions. The extent and directionality of estimates were preserved across all robustness assessments and subset analyses.

CONCLUSIONS AND RELEVANCE: In this cross-sectional study using a difference-in-differences approach, PE acquisition had no substantial association with the patient-level outcomes examined, although it was associated with a moderate improvement in mortality among Medicare beneficiaries hospitalized with AMI.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Cerullo M, Yang K, Joynt Maddox KE, et al. Association Between Hospital Private Equity Acquisition and Outcomes of Acute Medical Conditions Among Medicare Beneficiaries. JAMA Netw Open. 2022. PMID: 35486398. doi:10.1001/jamanetworkopen.2022.9581

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。